First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
In 2022, the Biden administration brought the Inflation Reduction Act into effect, with the aim to provide better and more equitable access to healthcare in the US. Part of the Act allows for Medicare to negotiate prices on prescription drugs for those on the federal health program aged 65 and above and/or are disabled.
The Centres for Medicare and Medicaid Services (CMS), the agency that oversees the Medicare program, selected the initial ten drug products for price negotiations in August 2023, and gave initial price offers in February 2024. The companies involved with these products had until March 2024 to respond. Companies can meet with the CMS up to three times for negotiations, after which final prices will be revealed on August 1, 2024. These prices will then come into effect in 2026 for those involved.
Companies with drug products in initial negotiations include Bristol Myers Squibb, Pfizer, Merck, Johnson & Johnson, AbbVie, Amgen, Boehringer Ingelheim Eli Lilly, and Novo Nordisk. However, not every pharma organisation is keen to negotiate smoothly This past March, AstraZeneca’s challenge to these price negotiations was rejected by a federal judge in Delaware after AstraZeneca was due to respond to an initial bid on the diabetes drug Farxiga. Such rulings have set precedents for the government when handling pharmaceutical companies looking to challenge the program on various grounds, including the stripping of property rights.
Sources:
1. US takes next step in Medicare drug price negotiations with pharma companies [Accessed April 5, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/us-takes-next-step-medicare-drug-price-negotiations-with-pharma-companies-2024-04-02/
2. Second judge upholds medicare drug price negotiation program [Accessed April 5, 2024] https://www.reuters.com/legal/second-judge-upholds-medicare-drug-price-negotiation-program-2024-03-01/
Related News
-
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Wegovy® – the weight-loss drug sparking a global race to end obesity
Wegovy®, the weight loss drug from Novo Nordisk has been creating headlines since it’s early testing phases, through it’s approval in June 2021 by the US FDA and January 2022 from the European Medicines Agency, and it continues to do so...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance